Tumor Hyperprogression in Squamous Cell Carcinomas of Head and Neck after Immunotherapy: Our Perspective
Head and Neck Squamous Cell Carcinoma (HNSCC) is the sixth most common cancer worldwide. Although there have been some advances in multimodality therapy, the overall 5-year survival rate remains poor approximately at 40%-50%. Currently, Immune Checkpoint Inhibitor (ICI) based Immunotherapies are being evaluated as an alternate treatment modality for recurrent/metastatic HNSCCs in clinical trials.
Authors
- Sanjeev Chawla (ORCID: https://orcid.org/0000-0001-6978-7284)
Publication Details
- Journal
- Otolaryngology Head & Neck Surgery
- Published
- 2024-10-16
- DOI
- https://doi.org/10.24966/ohns-010x/100103
- Primary Topic
- Immunotherapy and Immune Responses
- Type
- article
- Field-Weighted Citation Impact
- 0.00